Short‐Term Effectiveness of a Stepped‐Care Model to Address Fear of Cancer Recurrence in Patients With Early‐Stage Melanoma.

Objective: To investigate the effectiveness of the Melanoma Care Programme when implemented into routine clinical practice coupled with fear of cancer recurrence (FCR) screening and a stepped‐care model of intervention delivery. Methods: Using a Type‐I hybrid effectiveness‐implementation design, individuals with stage 0‐II melanoma and a Fear of Cancer Recurrence Inventory FCR severity score of ≥ 13 were offered the Melanoma Care Programme. The programme included a psychoeducational booklet and 3 to 5 psychotherapeutic telehealth sessions with a clinical psychologist, timed around routine dermatological appointments. Multivariable linear mixed modelling was used to analyse the effect of the intervention at 1‐week post‐intervention on patient‐reported outcomes, including FCR severity (primary outcome), symptoms of depression, anxiety, and stress, melanoma‐related knowledge, and health‐related quality of life. Results: One hundred and twelve participants completed the intervention from 146 participants screened for FCR. Adjusted multivariable linear mixed modelling demonstrated that participants who received the intervention reported a reduced FCR severity at 1‐week post‐intervention (mean change: −3.81 [95% CI: −4.67, −2.95], p < 0.001) compared to baseline. Participants also reported improvements in melanoma‐related knowledge (mean change: 0.64 [95% CI: 0.13, 1.15], p = 0.014), depressive symptoms (mean change: −1.41 [95% CI: −1.92, −0.90], p < 0.001), anxiety (mean change: −1.05 [95% CI: −1.48, −0.61], p < 0.001), stress (mean change: −1.58 [95% CI: −2.22, −0.93], p < 0.001), and health‐related quality of life (mean change: 4.05 [95% CI: 2.84, 5.26], p < 0.001). Conclusions: The Melanoma Care Programme maintained effectiveness when implemented into routine clinical practice with the addition of FCR screening and a stepped care model of delivery. Trial Registration: This study is registered with the Australia and New Zealand Clinical Trials Register (ACTRN12621000145808) [ABSTRACT FROM AUTHOR]